Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
Top Cited Papers
Open Access
- 27 September 2012
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 41 (6), 1393-1400
- https://doi.org/10.1183/09031936.00125812
Abstract
Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with worse treatment outcomes for patients, including higher mortality, than for drug-sensitive tuberculosis. Delamanid (OPC-67683) is a novel anti-TB medication with demonstrated activity against multidrug-resistant disease. Patients who participated in the previously reported randomised, placebo-controlled trial of delamanid and the subsequent open-label extension trial were eligible to participate in a 24-month observational study designed to capture treatment outcomes. Treatment outcomes, as assessed by clinicians and defined by the World Health Organization, were categorised as favourable and unfavourable. Delamanid treatment groups were combined for analysis, based on their duration of treatment. In total, for 421 (87.5%) out of 481 patients from the original randomised controlled trial, consent was granted for follow-up assessments. Favourable outcomes were observed in 143 (74.5%) out of 192 patients who received delamanid for ≥6 months, compared to 126 (55%) out of 229 patients who received delamanid for ≤2 months. Mortality was reduced to 1.0% among those receiving long-term delamanid versus short-term/no delamanid (8.3%; p<0.001). Treatment benefit was also seen among patients with extensively drug-resistant TB. This analysis suggests that treatment with delamanid for 6 months in combination with an optimised background regimen can improve outcomes and reduce mortality among patients with both multidrug-resistant and extensively drug-resistant TB.Keywords
This publication has 26 references indexed in Scilit:
- Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 PatientsPLoS Medicine, 2012
- Tuberculosis treatment outcome monitoring in European Union countries: systematic reviewEuropean Respiratory Journal, 2012
- Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?European Respiratory Journal, 2012
- Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistanceEuropean Respiratory Journal, 2012
- Tuberculosis: cost of illness in GermanyEuropean Respiratory Journal, 2012
- Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysisEuropean Respiratory Journal, 2011
- Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-AnalysisPLOS ONE, 2009
- Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysisThe Lancet Infectious Diseases, 2009
- OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In MicePLoS Medicine, 2006
- Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaThe Lancet, 2006